Aberdeen Group
RNAM

Aberdeen Group’s Avidity Biosciences RNAM Stock Holding History

Aberdeen Group’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-304,828
Closed -$13.3M – 983
2025
Q3 		$13.3M Buy
304,828
+25,000
+9% +$1.01M 0.02% 547
2025
Q2 		$7.95M Hold
279,828
– – 0.01% 648
2025
Q1 		$8.26M Buy
279,828
+234,916
+523% +$7.32M 0.02% 610
2024
Q4 		$1.31M Buy
44,912
+20,076
+81% +$839K ﹤0.01% 801
2024
Q3 		$1.14M Sell
24,836
-10,802
-30% -$469K ﹤0.01% 802
2024
Q2 		$1.46M Sell
35,638
-93,776
-72% -$2.69M ﹤0.01% 788
2024
Q1 		$3.3M Hold
129,414
– – 0.01% 729
2023
Q4 		$1.17M Buy
+129,414
New +$865K ﹤0.01% 823

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Aberdeen Group's RNAM Position: Q4 2025 in Review

Aberdeen Group sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 304,828 shares — an estimated $13.3M sold.

Aberdeen Group first reported a position in RNAM in Q4 2023 and held it in 8 quarters. The position peaked at $13.3M in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Aberdeen Group reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Aberdeen Group sold 304,828 Avidity Biosciences shares in Q4 2025, an estimated $13.3M.
  • Aberdeen Group first reported a position in Avidity Biosciences in Q4 2023 and held it in 8 quarters.
  • Aberdeen Group's Avidity Biosciences position peaked at $13.3M in Q3 2025.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.